LakeShore Biopharma Announces Receipt of Buyer Group Notice and Postponement of Extraordinary General Meeting of Shareholders
LakeShore Biopharma Announces Receipt of Buyer Group Notice and Postponement of Extraordinary General Meeting of Shareholders is drawing significant interest across the industry.
BEIJING, Feb. 6, 2026 /PRNewswire/ -- LakeShore Biopharma Co., Ltd ('LakeShore Biopharma' or the 'Company') (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it has received a notice, dated February 4, 2026, from legal counsel to a group (the 'Buyer Group') consisting of Oceanpine Skyline Inc. ('Parent'), Oceanpine Merger Sub Inc. ('Merger Sub'), Oceanpine Capital Inc., Oceanpine Investment Fund II LP, Crystal Peak Investment Inc., Adjuvant Global Health Technology Fund, L.P., Adjuvant Global Health Technology Fund DE, L.P., Superstring Capital Master Fund LP, MSA GROWTH FUND II, L.P., and Epiphron Capital (Hong Kong) Limited, relating to the previously announced going-private transaction of the Company whereby the Buyer Group agreed to take the Company private at a price of $0.90 per share pursuant to an Agreement and Plan of Merger (the 'Merger Agreement'), dated November 4, 2025, by and among the Company, Parent and Merger Sub.
Experts suggest this could influence future trends and innovation in the sector.
More updates are expected as the story develops.
Related Articles
- Maruti Suzuki Drives Innovation with Automated Test Tracks in Andhra Pradesh
- Quantum Valley Project Launched in Amaravati
- Blue Owl CEO: We see no red flags in ‘pristine’ software portfolio
- India's Quantum Leap: Amaravati Paves the Way
Source: Original →